Upgrade to SI Premium - Free Trial

Catalyst Pharmaceuticals (CPRX)

31.49 0.00 (0.00%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Curran Daniel J. July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Tierney David S July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Thompson Tamar July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Elsbernd Brian July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Miller Steve July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Russo Gregg July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: MCENANY PATRICK J July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Del Carmen Jeffrey July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Sundaram Preethi July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Daly Richard J July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Andrews William T. July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Kalb Michael Wayne July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: DENKHAUS DONALD A July 17, 2026 4:16 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jul 15 Filed by: Harper Molly July 17, 2026 4:16 PM - SEC Filing Form EFFECT CATALYST PHARMACEUTICALS July 17, 2026 6:04 AM - SEC Filing Form EFFECT CATALYST PHARMACEUTICALS July 17, 2026 6:04 AM - SEC Filing Form EFFECT CATALYST PHARMACEUTICALS July 17, 2026 6:03 AM - SEC Filing Form EFFECT CATALYST PHARMACEUTICALS July 17, 2026 6:03 AM - SEC Filing Form EFFECT CATALYST PHARMACEUTICALS July 17, 2026 6:03 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:03 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form S-8 POS CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form POS AM CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form POSASR CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form POS AM CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form POS AM CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form POS AM CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form POS AM CATALYST PHARMACEUTICALS July 16, 2026 6:02 AM - SEC Filing Form 8-K CATALYST PHARMACEUTICALS For: Jul 15 July 16, 2026 6:01 AM - SEC Filing Angelini Pharma acquires Catalyst at $31.50 a share for $4.1B July 16, 2026 3:36 AM - StreetInsider Angelini Pharma Completes Acquisition of Catalyst Pharmaceuticals July 16, 2026 3:36 AM - StreetInsider Form 25-NSE CATALYST PHARMACEUTICALS Filed by: Nasdaq Stock Market LLC July 15, 2026 9:56 AM - SEC Filing Solaris Energy Infrastructure Set to Join S&P SmallCap 600 July 9, 2026 5:48 PM - PR NewsWire Solaris Energy Infrastructure to Join S&P SmallCap 600 July 9, 2026 5:18 PM - StreetInsider Form 8-K CATALYST PHARMACEUTICALS For: Jul 08 July 8, 2026 5:30 PM - SEC Filing Form DEFA14A CATALYST PHARMACEUTICALS June 30, 2026 5:23 PM - SEC Filing Form 8-K CATALYST PHARMACEUTICALS For: Jun 30 June 30, 2026 4:58 PM - SEC Filing Catalyst Pharma reports vamorolone Phase 1 data on immune activity June 30, 2026 8:04 AM - StreetInsider Vamorolone Demonstrates On-Target Glucocorticoid Activity Without the Immunosuppression Characteristic of Traditional Corticosteroids at Clinical Doses June 30, 2026 8:03 AM - StreetInsider Form 8-K CATALYST PHARMACEUTICALS For: Jun 22 June 23, 2026 5:15 PM - SEC Filing Form DEFM14A CATALYST PHARMACEUTICALS June 8, 2026 4:09 PM - SEC Filing Form 4 CATALYST PHARMACEUTICALS For: Jun 03 Filed by: Andrews William T. June 5, 2026 5:01 PM - SEC Filing Form PREM14A CATALYST PHARMACEUTICALS For: May 28 May 28, 2026 5:49 PM - SEC Filing H.C. Wainwright Downgrades Catalyst Pharmaceutical Partners (CPRX) to Neutral May 28, 2026 10:23 AM - StreetInsider Form DEFA14A CATALYST PHARMACEUTICALS May 12, 2026 9:05 AM - SEC Filing Form 8-K CATALYST PHARMACEUTICALS For: May 11 May 11, 2026 4:35 PM - SEC Filing Catalyst Pharmaceuticals Reports First Quarter 2026 Financial Results May 11, 2026 4:12 PM - Globe NewsWire Form 10-Q CATALYST PHARMACEUTICALS For: Mar 31 May 11, 2026 4:11 PM - SEC Filing Form DEFA14A CATALYST PHARMACEUTICALS May 8, 2026 5:21 PM - SEC Filing Citi Downgrades Catalyst Pharmaceutical Partners (CPRX) to Neutral May 8, 2026 10:05 AM - StreetInsider Form DEFA14A CATALYST PHARMACEUTICALS May 7, 2026 5:28 PM - SEC Filing Catalyst Pharmaceuticals Cancels First Quarter 2026 Conference Call and Webcast May 7, 2026 4:02 PM - Globe NewsWire Oppenheimer Downgrades Catalyst Pharmaceutical Partners (CPRX) to Perform May 7, 2026 12:40 PM - StreetInsider Form DEFA14A CATALYST PHARMACEUTICALS May 7, 2026 9:01 AM - SEC Filing Form 8-K CATALYST PHARMACEUTICALS For: May 06 May 7, 2026 8:46 AM - SEC Filing Stephens Downgrades Catalyst Pharmaceutical Partners (CPRX) to Equal Weight May 7, 2026 8:02 AM - StreetInsider Catalyst Pharmaceuticals settles FIRDAPSE patent case with Hetero Labs May 7, 2026 5:59 AM - StreetInsider Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion May 7, 2026 3:25 AM - StreetInsider Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease May 7, 2026 3:25 AM - Globe NewsWire Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Hetero Labs Ltd. May 7, 2026 2:44 AM - Globe NewsWire Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion May 7, 2026 2:14 AM - StreetInsider Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease May 7, 2026 2:14 AM - StreetInsider Form 10-K/A CATALYST PHARMACEUTICALS For: Dec 31 April 30, 2026 4:32 PM - SEC Filing Catalyst Pharmaceuticals to Report First Quarter 2026 Financial Results on May 11, 2026 April 28, 2026 8:03 AM - Globe NewsWire BofA Securities stays Buy on Catalyst Pharma (CPRX) amid Angelini acquisition interest reports April 27, 2026 4:15 PM - StreetInsider Catalyst Pharmaceuticals (CPRX) 3600 contracts of May 30 calls trade, share price up 7.9% April 27, 2026 3:36 PM - StreetInsider Italy's Angelini Said To Explore Acquisition Of Catalyst Pharma - Bloomberg April 27, 2026 12:05 PM - StreetInsider Full Article List